300759 Stock Overview
Provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Pharmaron Beijing Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥28.11 |
| 52 Week High | CN¥36.42 |
| 52 Week Low | CN¥17.70 |
| Beta | 0.84 |
| 11 Month Change | 2.03% |
| 3 Month Change | 42.84% |
| 1 Year Change | -16.16% |
| 33 Year Change | -65.10% |
| 5 Year Change | 23.39% |
| Change since IPO | 473.41% |
Recent News & Updates
Recent updates
At CN¥29.44, Is It Time To Put Pharmaron Beijing Co., Ltd. (SZSE:300759) On Your Watch List?
Nov 15
Pharmaron Beijing Co., Ltd. (SZSE:300759) Shares Fly 29% But Investors Aren't Buying For Growth
Sep 27Pharmaron Beijing Co., Ltd. (SZSE:300759) Shares Could Be 22% Below Their Intrinsic Value Estimate
Sep 20Pharmaron Beijing Co., Ltd.'s (SZSE:300759) Intrinsic Value Is Potentially 69% Above Its Share Price
May 12Pharmaron Beijing Co., Ltd.'s (SZSE:300759) 27% Share Price Surge Not Quite Adding Up
Mar 04Pharmaron Beijing (SZSE:300759) Seems To Use Debt Quite Sensibly
Feb 27Shareholder Returns
| 300759 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | -10.5% | -11.4% | -6.7% |
| 1Y | -16.2% | -33.7% | 1.9% |
Return vs Industry: 300759 exceeded the CN Life Sciences industry which returned -30.6% over the past year.
Return vs Market: 300759 underperformed the CN Market which returned 4% over the past year.
Price Volatility
| 300759 volatility | |
|---|---|
| 300759 Average Weekly Movement | 12.2% |
| Life Sciences Industry Average Movement | 10.2% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CN Market | 12.5% |
| 10% least volatile stocks in CN Market | 5.5% |
Stable Share Price: 300759's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 300759's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 20,342 | Boliang Lou | www.pharmaron.com |
Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, and internationally. The company offers laboratory chemistry services, including medicinal and synthetic chemistry, chemistry for new modalities, radiolabelling and radiosynthesis, analytical and purification chemistry, DNA-encoded libraries, cheminformatics, and computer-aided drug design; bioscience services, such as structural biology, in vitro biology, DMPK, in vivo pharmacology, and compound management services; chemistry, manufacturing, and controls services. It also provides clinical development services, including integrated radio labelled science, clinical development, and clinical trial recruitment services; safety assessment, integrated drug discovery, and bioanalysis services; and biologics and cell and gene therapy services, comprising biologics laboratory, biologics CDMO, cell and gene therapy laboratory, and gene therapy CDMO services.
Pharmaron Beijing Co., Ltd. Fundamentals Summary
| 300759 fundamental statistics | |
|---|---|
| Market cap | CN¥44.54b |
| Earnings (TTM) | CN¥1.88b |
| Revenue (TTM) | CN¥11.80b |
26.5x
P/E Ratio4.2x
P/S RatioIs 300759 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300759 income statement (TTM) | |
|---|---|
| Revenue | CN¥11.80b |
| Cost of Revenue | CN¥7.77b |
| Gross Profit | CN¥4.02b |
| Other Expenses | CN¥2.14b |
| Earnings | CN¥1.88b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.06 |
| Gross Margin | 34.12% |
| Net Profit Margin | 15.97% |
| Debt/Equity Ratio | 38.7% |
How did 300759 perform over the long term?
See historical performance and comparison